Goodwin Procter LLP advised Repertoire Immune Medicines on the deal.Repertoire Immune Medicines announced the completion of its $189 million Series B financing. Joining Flagship Pioneering, Repertoire’s institutional…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
